Palgesic Retard (Tapentadol)

Tapentadol, the active ingredient in Palgesic Retard, is an opioid analgesic presented as a controlled‑release formulation for oral use. It is indicated for the management of moderate to severe chronic pain in adult patients when alternative treatments are inadequate. GNH USA supplies Palgesic Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Tapentadol is used in pain management pathways for several chronic pain conditions. - Chronic low back pain: provides sustained relief of moderate to severe pain over 24 hours. - Osteoarthritis pain: improves functional mobility by reducing pain intensity. - Neuropathic pain associated with diabetic peripheral neuropathy: lessens pain spikes and improves quality of life.

Tapentadol may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Constipation: reduced bowel movements. - Dizziness: transient light‑headedness. - Headache: mild throbbing pain. - Somnolence: feeling unusually sleepy. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that may require medical attention. - Seizures: rare occurrence, especially at high doses or with interacting drugs. - Severe hypotension: sudden drop in blood pressure. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Dependence or abuse potential: risk of developing opioid use disorder. - adrenal insufficiency: rare hormonal imbalance affecting stress response.

When prescribing Tapentadol, clinicians should consider several safety measures to minimize risk. - Assess pain severity and prior opioid exposure: ensure suitability for opioid therapy. - Evaluate renal and hepatic function: adjust use in impairment. - Monitor for signs of respiratory depression: especially during dose escalation. - Counsel patients on constipation management: use laxatives or diet changes. - Advise against concurrent use with CNS depressants: increased sedation risk. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Tapentanol may interact with a variety of medicines; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - CNS depressants (benzodiazepines, barbiturates): additive sedation and respiratory depression. - CYP2D6 inhibitors (paroxetine, fluoxetine): increased tapentadol plasma levels.

Moderate Interactions (Monitor Closely): - Serotonergic agents (tramadol, SSRIs, SNRIs): potential serotonin syndrome. - Antihistamines (diphenhydramine): enhanced drowsiness. - Alcohol: increased central nervous system depression.